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ABSTRACT 
Recent advances in novel drug delivery (NDDS) aims to enhance safety and efficacy of drug molecule by formulating a convenient dosage 
form for ease of administration and to achieve better patient compliance. Depending upon functionality, it is possible to design different 
dosages forms which fulfill the therapeutic needs of the patient with improved bioavailability of poorly water soluble drugs, taste masking 
and preparation of oral dispersible tablets, MUPS and multiple unit formulations. The hot-melt technology is one of the most commonly used 
method,  is devoid of solvent use, solvent disposal, solvent evaporation and solvent treatment is not required.  
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INTRODUCTION 
A dosage form is a drug delivery systems designed to deliver 
the active ingredient(s) to the body. It must produce the 
same therapeutic response each time it is administered. The 
most common and popular route for administration of a 
dosage form or drug delivery system is oral. Amongst the 
various drug formulations or delivery systems for oral 
administration, the solid dosage forms are most widely used 
and produced. Tablets and capsules are two of the most 
predominant solid oral dosage forms.1 
The use of hot-melt extrusion (HME) within the 
pharmaceutical industry is steadily increasing, due to its 
proven ability to efficiently manufacture novel products. The 
process has been utilized readily in the plastics industry for 
over a century and has been used to manufacture medical 
devices for several decades. The development of novel drugs 
with poor solubility and bioavailability brought the 
application of HME into the realm of drug-delivery systems. 
This has specifically been shown in the development of drug-
delivery systems of both solid dosage forms and transdermal 
patches. HME involves the application of heat, pressure and 
agitation through an extrusion channel to mix materials 
together, and subsequently forcing them out through a die. 
Twin-screw extruders are most popular in solid dosage form 
development as it imparts both dispersive and distributive 
mixing. It blends materials while also imparting high shear to 
break-up particles and disperse them. HME extrusion has 
been shown to molecularly disperse poorly soluble drugs in 
a polymer carrier, increasing dissolution rates and 
bioavailability. The most common difficulty encountered in 
producing such dispersions is stabilization of amorphous 
drugs, which prevents them from recrystallization during 
storage. Pharmaceutical industrial suppliers, of both 
materials and equipment, have increased their development 
of equipment and chemicals for specific use with HME. 
Clearly, HME has been identified as an important and 
significant process to further enhance drug solubility and 
solid-dispersion production.5-6 
Hot-melt extrusion (HME) processing were come in action in 
the early 1930s, and during that time, and became the most 
widely applied processing technology in the plastic, rubber, 
and food industries. The application of HME expanded to the 
pharmaceutical industry at the beginning of the seventies for 
formulation and product development as well as 
manufacturing. The first application of HME as a 
manufacturing tool in the pharmaceutical industry was 
investigated by El-Egakey.1 using poly (vinyl acetate-co-
methacrylic acid) and epoxy resin containing a secondary 
amine as a polymeric carrier1. HME includes a continuous 
process of pumping polymeric materials in a rotating screw 
temperatures usually above their glass transition 
temperature (Tg) and often at temperature above the 
melting point to achieve molecular level mixing of the active 
compounds and binders2-3 resulting into an amorphous 
product with a uniform shape and density, with improved 
dissolution profile of the poorly water-soluble drug4. HME 
technology having several advantages over conventional 
pharmaceutical manufacturing processes such as shorter 
and more efficient time to achieve the final product, 
ecofriendly due to the elimination of solvent use, and 
increased efficiency of drug delivery to the patient. As a 
result, HME has emerged as an alternative platform 
technology to other traditional techniques for manufacturing 
pharmaceutical dosage forms such as tablets, capsules, films, 
and implants for drug delivery via oral, transdermal, and 
transmucosal routes. The introduction of HME to 
pharmaceutical formulation development has made 
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sophisticated equipment such as the extruder, customized 
downstream auxiliary equipment, and monitoring tools 
available for application in evaluating the performance and 
product quality. To date, several research articles have been 
published describing the use of HME as the novel technique 
of choice in dealing with the day-to-day formulation 
challenges of new active pharmaceutical ingredients (APIs). 
Moreover, numerous aspects of the HME technology have 
been extensively cited in the literature. Additionally, the 
number of patents based on HME techniques has risen 
steadily worldwide in recent decades.4-13 
Hot-melt technology  
Hot-melt technology is a process in which molten 
excipient(s) and/or drug are either layered on substrate, 
congealed alone or with excipient(s) using one of the 
following processes to design to improved drug delivery 
systems – 
a) Hot-melt coating 
b) Spray congealing 
c) Hot-melt extrusion and spheronization 
d) Hot-melt extrusion 
e) Hot-melt granulation. 
Hot-melt coating: Hot-melt coating involves spraying of 
molten excipient(s) or mixture of molten excipient(s) and 
drugs either in suspended or dissolved form onto a substrate 
during fluidization in a fluid-bed coating device leading to 
solidification of the substrate on cooling and form a thin 
homogenous film.16 
Spray congealing: Spray congealing is a method of 
converting molten excipient(s) with drug into dry powder, 
granules or spheroids by spraying through suitable 
pneumatic nozzles in a stream of co-current or counter-
current cold fluidized air.17 
Hot-melt extrusion and spheronization: Hot extrusion 
spheronization is a multiple step process. The process 
involves hot-melt extrusion of low melting point excipient(s) 
with drug followed by hot-melt spheronization and gradual 
cooling during spheronization to produce uniform size 
spherical congealed particles, called as spheroids, pellets, 
beads or matrix pellets.18 
Hot-melt extrusion: Hot-melt extrusion is the process of 
converting a uniform mixture of excipient(s) and drug into a 
product of uniform shape and density by forcing it through a 
die under controlled conditions of temperature to convert 
the molten clear mass into solid mass.19 
Hot-melt granulation: Hot-melt granulation is the process 
of formation of agglomerates of mixture of excipient(s) and 
active pharmaceutical ingredient(s) using molten mass as 
binder under high shear mixing.20 
Key Points of Hot-Melt Technology 
The various advantages of hot-melt technology in drug 
delivery are listed below: 17 
1. Neither solvent(s) nor water is used in the process. 
2. Fewer processing steps are needed, thus shorter 
processing times. 
3. Fewer processing steps, thus less critical process 
parameters. 
4. Good stability at varying pH and moisture levels. 
5. Used for improved drug delivery. 
6. Overall low production cost. 
7. Since organic solvents are avoided, the process is 
environment friendly as well as safe for personnel and 
facility where processing is done. 
Limitations of Hot-Melt Technology 
The various demerits of hot-melt technology in formulation 
design are as under: 
1. Requires high energy input. 
2. Cannot be applied to heat-sensitive materials. 
3. Specially designed equipment’s are required. 
4. Limited lipid excipients and thus limitations in 
formulation design. 
Application of hot melt Technology 
Lipid-Based systems for Bio enhancement: 
Bioavailability18 refers to the rate and extent of the drug 
absorption in the systemic circulation after administration 
by a given route. For oral administration, bioavailability of 
drugs depends on solubility of the drug in the 
gastrointestinal fluid along with permeability of drug which 
governs the dissolved drug absorption into the 
gastrointestinal membrane. 
Taste Masking: Taste is one of the most important 
parameter governing patient compliance. Oral 
administration of bitter drugs with an acceptable degree of 
palatability is a key issue for health care providers, especially 
for pediatric patients. Use of flavor/sweetener and 
physical/chemical methods to prevent the drug substances 
from interaction with the taste buds are the two approaches 
of masking the nauseous or bitter taste of the medicaments. 
The major disadvantage of physical method of the taste 
masking by polymer require organic solvents to dissolve the 
polymer and difficult processbility for example, solvent 
evaporation, organic phase separation methods, etc. One of 
the best physical approaches to mask the drug taste is by the 
spray congealing technique,21 the microspheres of drug 
entrapped in lipids, prepared by spray congealing, mask the 
bitter taste of the drug and improve palatability.22 
Multiple-Unit Formulations: Multiple unit formulation 
such as pellets is widely employed for modified release 
dosage forms. The conventional means for manufacturing 
these dosages forms include drug layering or extrusion-
spheronization followed by functional coating. The drug 
release is controlled by varying the thickness of the coating 
and chemical nature of polymers.23 Traditionally polymers 
were dissolved in a solvent (water or organic) prior to 
spraying. During and after coating the solvent must be 
evaporated. The use of solvents nowadays is under 
constraint due to the residual solvent in traces levels, while 
recovering a solvent often proves expensive. Due to long 
evaporation time water could also be a problem. In order to 
avoid such problems and to reduce costs. A better alternative 
is pellets prepared by the spray congealing which is a single 
step process that provides drug particles embedded in the 
matrix of the wax so that drug release occurs by diffusion 
and erosion mechanism. To control drug release it is 
appealing to use a wax of different lyophilicity as coating 
materials. Waxes of varying lyophilicity are available and can 
be used to regulate the customized drug release from 
multiunit controlled release pellets. The application of 
saturated polyglycolized glyceride (Gelucire® 50/02) and 
glycerol palmitostearate (Precirol® ATO5) as drug release 
regulators for propranolol Hydrochloride pellets.22-25 
Multiple-Unit Pellet System (MUPS): In pharmaceutical 
industry and research perspective, the term in general refers 
to MUPS compacted into tablets. Thus, the resulting tablets 
prepared by compaction of modified release coated 
multiparticulates or pellets are called as MUPS.23  
It is recognized that oral administration of a multi-unit 
controlled release dosage form is preferred over single 
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dosage unit due reduction in inter- and intra-subject 
variability in drug absorption and clinical response. The 
number of micropellets per MUPS dosage form is much more 
therefore possibility of dose dumping (in stomach) and 
incomplete drug release is further minimized. A particular 
problem occurs if the micropellets coated with a polymer. 
Polymer film which controlled drug release, as the tableting 
process can cause severe damage to the film altering the 
release characteristics from the micropellets. The 
compaction of micropellets requires special efforts. The hot-
melt technology offers the matrix micropellets having ideal 
characteristics for compaction i.e. retarding drug release in 
GI fluid while providing cushion during pellet compaction.24-
27 
Melt Granulation: The granules for modified release or 
conventional release tablets can also be manufactured by the 
hot-melt technology. The fluid hot-melt granulations for the 
preparation of granules for tableting.24 Melt granulation are 
also used for low dose modified release tablet. It eliminates 
the milling and sifting step during tablet manufacturing.28  
Excipient for Hot Melt Technology:  
Lipids are defined as amphiphilic molecules which are 
naturally occurring and semisynthetic molecules in nature 
include fatty acid, fatty alcohol, wax and phospholipids etc. 
The amphiphilic nature of some lipids allows them to form 
structures such as micelles, vesicles and liposomes etc. in an 
aqueous environment.18 
Fatty Acids: A fatty acid29 is a carboxylic acid with a long 
unbranched aliphatic chain which is either saturated or 
unsaturated. 
i) Saturated fatty acids  
ii) Unsaturated fatty acids  
Fatty Alcohols 
Fatty alcohols30 are aliphatic alcohols consisting of a chain of 
8 to 22 carbon atoms. Fatty alcohols usually have even 
number of carbon atoms and a single alcohol group (-OH) 
attached to the terminal carbon. 
Glycerolipids: Glycerolipids are composed mainly of mono-, 
di-, and tri-substituted glycerol’s. Thus glycerolipids are 
glycerol ester of the fatty acid and fabricating by 
incorporating the functional moiety to modify 
physicochemical properties. Depending upon substitution of 
the hydroxyl group of the glycerol by fatty acid they are as 
monoglycerides, diglycerides and triglycerides. 
Waxes and Oils: Waxes are organic compounds that 
characteristically consist of a long alkyl chains. Natural 
waxes are typically esters of fatty acids and long chain 
alcohols. Synthetic waxes are long-chain hydrocarbons 
lacking functional groups.32 
Phospholipids: Phospholipids are a class of lipids and are a 
major component of all cell membranes as they can form 
lipid bilayer. Most phospholipids contain diglycerides, a 
phosphate group and a simple organic molecule such as 
choline, lecithin (phosphatidyl choline).18 
Surfactants: A surfactant is organic compound which has 
both hydrophilic and hydrophobic portions which reduces 
surface tension between two immiscible liquid which 
facilitate the immersion or dispersion of the one phase into 
another phase. Surfactant classified according to the 
composition of their head: anionic, cationic, amphoteric and 
non-ionic.33  
Non-Lipidic Excipients 
Butylated hydroxyanisole: Butylated hydroxyanisole is an 
antioxidant with some antimicrobial properties.34-35 It is 
used in a wide range of cosmetics, foods and 
pharmaceuticals having melting point 47oC. It is practically 
insoluble in water, soluble in methanol, freely soluble in oil 
and glyceryl mono-oleate. It is used to delay or prevent 
oxidative rancidity of fats and oils. 
Butylated hydroxytoluene: Butylated hydroxytoluene is 
used as an antioxidant in cosmetics, foods, and 
pharmaceuticals having melting point 70oC. It is freely 
soluble in fixed oils and mineral oil and more soluble than 
butylated hydroxyanisole. It is mainly used to delay or 
prevent the oxidative rancidity of fats and oils.36 
Citric acid: Citric acid exist as either monohydrate or 
anhydrous material and used in pharmaceutical 
formulations and food products as an acidifying agent, 
antioxidant, buffering agent, chelating agent and 
preservative having melting point 100oC (softens at 75oC).38 
Meglumine: Meglumine is 1-deoxy-1-(methylamino)-D-
glucitol. Meglumine is used as a pH-adjusting agent and 
solubilizing agent having melting point 100 oC (softens at 
75oC).39 
Polyethylene glycol (PEG): Depending upon the average 
molecular weight, PEGs are available in various grades i.e. 
liquid, semisolid and solid. They are available in grades and 
vary their physical properties. They have a slight but 
characteristic odour and a bitter taste. They are used as 
solubilizer and as thermal carrier in hot-melt technology.40 
Equipment for Hot Melt Technology 
The hot-melt process involve melting of required excipients, 
raising their temperature slightly above their melting point 
with constant stirring at the constant temperature followed 
by spraying, congealing or coating etc. The process 
conditions and equipment for hot-melt process has been 
published by Jones and Percel.15 Various types of equipment 
can be used for the hot-melt processes such as fluid bed 
coater, turbo jet and conventional solid pan. The latter 
requires material holding tank for melting of the lipid and 
facility to keep it in molten and sprayable state throughout 
the process.  
The material holding tank jacketed with electric heater 
having pneumatic stirrer is used to melt material under 
controlled temperature and stirring. The butterfly valve 6 is 
kept closed that allows the molten mass to circulate from 
tank through valve 4 and 5 using centrifugal monoblock or 
peristaltic pump and then back in tank. The process is 
continued until all tubings get equilibrated with desired 
temperature. Once the temperature is reached, valve 4 is 
closed and material is allowed to go back into the tank. The 
speed of pump is adjusted according to requirement, valve 5 
is closed and valve 4 and 6 are opened and thus the molten 
material is circulated through valve 6 to spray the molten 
material without compromising the clogging of tubes and 
spray nozzle. The spray nozzle can be equipped with top, 
bottom and tangential spray fluid-bed coater. Thus, top 
spray method is used to prepare granules, spray congealed 
microparticles and pellets while bottom spray is used to coat 
the pellets by hot-melt process. 
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Figure 1: Material holding tank equipped with facility for 
spray congealing. 
Table 1: Description of Material Holding Tank 
S.N. Components of Material holding tank  
1 Material holding tank  
2 Pneumatic stirrer  
3 Centrifugal monoblock / peristaltic pump  
4 Butterfly valve  
5  Electric heating band  
6 Tank insulation  
7 Interconnecting piping with triclover sanitary fitting  
 
8 Temperature probe  
 
Table 2: Equipment’s used in the Preparation of Drug ER MUPS 
S.N. Equipment Purpose 
1 Material holding tank equipped with facility for spraying 
molten mass 
To melt the lipid and maintain temperature during 
processing 
2 Fluid bed equipment (top spray and bottom spray) To spray congeal the granules and its coating 
3 Vibratory sifter  and sieves of various sizes  Sieving and grading of granules 
4 Octagonal  blender Blending 
5 Tablet press (Cadmach) Compression of tablets 
 
Method of Preparation of Extended- Release MUPS  
Design of extended-release MUPS involved three steps – 
1. Design, composition and preparation of Drug spray 
congealed matrix pellets. 
2. Design and composition of top coating on Drug spray 
congealed matrix pellets. 
3. Design, composition and compaction of Drug extended-
release pellets into extended-release MUPS. 
 
Evaluation of Extended- Release MUPS 
Photomicrography of Extended-Release Pellets and 
MUPS: Magnified photographs of spray congealed pellets of 
various designed formulation prototypes were taken using 
digital microscope Intelplay QX3 attached to a personal 
computer. The photographs were used to examine the 
sphericity and smoothness, imperfections on the surface. 
Evaluation of Physical Parameters of MUPS: Extended-
release MUPS tablets were evaluated for physical parameters 
such as mechanical strength (unofficial tests) and friability34, 
39 and disintegration time40. Test for uniformity of tablet 
weight was not done since the batch size was small. 
In Vitro Dissolution Studies of Extended-Release Pellets 
and its MUPS: Dissolution tests were performed in 
accordance with USP 32-NF27 and using apparatus 2 
(paddle). 39-54 
Analysis of Content in Prepared Formulations: The 
reagents and procedure for determining, drug release and 
drug content in spray congealed extended-release pellets, 
top coated extended-release pellets and MUPS were 
according to USP32-NF27.43-49 
  .  
Figure 2: Flow chart of steps involved in the preparation of 
Drug extended-release MUPS tablet.36
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Table 3:  In Vitro Dissolution Parameters for ER Pellets and MUPS of as per USP. 
Dissolution Parameters Settings/Requirements 
USP dissolution test In USP32-NF27 monograph for  Extended Release Tablet  
Apparatus type USP type 2 (paddle) 
Speed  50 rpm 
Dissolution media pH 6.8 phosphate buffer, 500 ml  
Temperature of media 370C ± 0.50C 
Sampling time points 1, 4, 8 and 20 hours 
 
Stability Studies on ER MUPS: MUPS samples of optimized 
batch were packaged in alu-alu blisters and stored under 
accelerated conditions (40oC and 75% RH)44-51 for three 
months.  After three months, the tablets were subjected to 
evaluation of disintegration time, in vitro dissolution and drug 
content which were then collectively analysed to evaluate the 
quality of extended-release MUPS prepared with produced 
pellets. 
Advantages of MUPS over Conventional Modified-
Release Formulations   
The various advantages of compacted MUPS over 
conventional modified-release tablets and/or 
multiparticulates filled capsules are as under – 
Pharmacokinetic advantages2, 38-51 
 Rapid but uniform transit of micro pellets contained in 
MUPS from the stomach into small intestine, owing to 
their small size, and thus lesser possibility of localized 
irritation, better and more uniform drug absorption and 
greater bioavailability. 
 Uniform emptying of micropellets from stomach into 
small intestine facilitates rapid dissolution of enteric 
coating and drug release resulting in early tmax and Cmax 
(peak time and peak plasma concentration) in case of 
delayed-release formulations. In case of controlled-
release preparations, drug release is more uniform and 
possibility of dose dumping is avoided with minimized 
tendency for inter-subject variations. 
Pharmacodynamics advantages46-54 
 Owing to rapid and uniform gastric emptying and 
subsequently uniform drug dissolution of pellets in the 
gastrointestinal tract due to their small size and larger 
surface, uniform drug absorption is facilitated which 
results in consistent and controlled pharmacological 
action. 
 A further reduction in inter-and intra-subject variability 
in drug absorption and clinical response is facilitated 
since the number of pellets per MUPS dosage form is 
much more than a conventional pellet-filled capsule and 
possibility of dose dumping (in stomach) and/or 
incomplete drug release is further minimized.  
 Reduces local irritation to gastrointestinal mucosa as the 
drug available in multiple units which disperse better in 
the gastrointestinal tract. 
Patient friendly dosage form48-52 
 Mouth disintegrating MUPS dosage form having a 
palatable taste is suitable for paediatric and geriatric 
patients who cannot swallow tablet or capsule, e.g. 
Prevacid® SoluTab.   It can also be administered via 
nasogastric tube (≥ 8 French). 
 The orodispersible MUPS medication can be taken 
without water, especially while travelling since the 
dosage form can be designed as orally disintegrating 
preparation that contains flavours and sweeteners that 
stimulate salivation and swallowing e.g. Prevacid® 
SoluTab. 
 Being tablets, quite unlike a capsule formulation, MUPS 
can be also designed into a divisible dosage form, without 
compromising the drug release characteristics of coated 
particles contained therein. e.g. Toprol-Xl® (Metoprolol 
Succinate Extended-Release Tablets) 
 The MUPS have lesser tendency of adhering to 
oesophagus during swallowing. 
 Smaller volume/size of tablet leads to better patient 
compliance than capsules. 
Processing advantages53 
 Greater physicochemical and microbiological stability of 
pellets owing to their embedment in inert matrix. 
 Rapidity of processing in comparison to capsules using 
existing tableting facility.52 
 Lower cost of processing owing to higher processing 
speed, elimination of capsule cost, etc. 
 The product is relatively tamper-proof. 
 Unlike conventional tablets, there is reduction in dust 
problems during compression. 
 Pellets intended for compaction into MUPS demonstrate 
excellent flow properties owing to their near spherical 
nature and thus easy to process into a tablet as compared 
to conventional granules used for tableting. Such 
compositions also require lesser amount of lubricants for 
tablet processing. 
Regulatory advantages 
 Extension of patent life. 
 Line extension of product. 
 Possibility of patenting and registering the product in 
various markets globally.  
CONCLUSION 
Hot-melt technology is used to design variety of oral dosages 
forms such as tablets with improved bioavailability of poorly 
water soluble drugs, taste masking and, MUPS and multiple 
unit formulations. Hot-melt technology is used to design 
different dosages forms and drug delivery systems which 
fulfill the therapeutic needs of the patient, which are cost-
effective and manufactured by eco-friendly process. Hot-melt 
technology is used to enhance the bioavailability of poorly 
water soluble and lipophilic drugs, taste masking of bitter 
drugs, fabrication of extended release multiparticulates and 
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